Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD
113.20
+1.31 (1.17%)
Apr 3, 2025, 3:43 PM EDT - Market open
1.17%
Market Cap 140.97B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
Shares Out 1.25B
EPS (ttm) 0.38
PE Ratio 297.29
Forward PE 14.23
Dividend $3.16 (2.80%)
Ex-Dividend Date Mar 14, 2025
Volume 6,620,143
Open 113.13
Previous Close 111.89
Day's Range 112.61 - 114.75
52-Week Range 62.07 - 119.96
Beta 0.34
Analysts Buy
Price Target 105.32 (-6.96%)
Earnings Date Apr 24, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $105.32, which is a decrease of -6.96% from the latest price.

Price Target
$105.32
(-6.96% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp.

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: AMZNGOOGGOOGLKLAC
1 day ago - CNBC Television

Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

2 days ago - CNBC

Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Opti...

Other symbols: AMATAPHBKBMYCTASEOGEQH
4 days ago - Seeking Alpha

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...

7 days ago - Market Watch

Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval

Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europ...

11 days ago - Seeking Alpha

Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding

Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.

15 days ago - Barrons

Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly

The Investment Committee debate the latest Calls of the Day.

Other symbols: LLYSBUXSHAKMMM
20 days ago - CNBC Television

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment port...

22 days ago - Business Wire

Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite ...

23 days ago - Seeking Alpha

Stocks beating the stock market's recent Trump slump have this in common

This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.

23 days ago - Market Watch

First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavi...

23 days ago - Business Wire

5 Big Biopharmaceutical Stocks That Are Finding Favor

AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.

Other symbols: ABBVAMGNJNJLLY
4 weeks ago - Barrons

Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants T...

4 weeks ago - Seeking Alpha

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings...

Other symbols: CORTPRVATGTXTKO
4 weeks ago - Invezz

Gilead Sciences sets aside $200 million to resolve HIV drug probe

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.

4 weeks ago - Reuters

Why Gilead Sciences Remains A Buy After A 40% Rally

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by...

5 weeks ago - Seeking Alpha

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer

LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to...

5 weeks ago - Business Wire

European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marketin...

5 weeks ago - Business Wire

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the trea...

5 weeks ago - Business Wire

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...

6 weeks ago - Business Wire

Calls of the Day: Gilead Sciences and Merck

The Investment Committee debate the Calls of the Day in two biotech names.

Other symbols: MRK
6 weeks ago - CNBC Television

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...

6 weeks ago - Business Wire

Josh Brown's best stocks

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his favorite stocks in the market right now.

Other symbols: CTVAUNP
6 weeks ago - CNBC Television

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.

7 weeks ago - Benzinga

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% effective...

7 weeks ago - Seeking Alpha